A 52-year-old man with cirrhosis presents with a hepatic nodule on imaging. Serum AFP is 450 ng/mL and PIVKA-II is 180 mAU/mL. Which single feature best distinguishes hepatocellular carcinoma (HCC) from benign cirrhotic nodules in this patient?

## Discriminating HCC from Benign Cirrhotic Nodules **Key Point:** While AFP alone has poor specificity for HCC in cirrhosis (many benign nodules and cirrhosis itself cause mild elevation), the combination of AFP >400 ng/mL AND PIVKA-II >40 mAU/mL has significantly higher specificity (>90%) for HCC diagnosis. ### Why PIVKA-II Adds Diagnostic Value PIVKA-II (Protein Induced by Vitamin K Absence-II, also called des-gamma-carboxyprothrombin) is produced specifically by HCC cells due to: - Impaired gamma-carboxylation in malignant hepatocytes - Minimal elevation in benign liver disease or non-HCC malignancies - Independent marker from AFP — detects ~40% of AFP-negative HCCs ### Diagnostic Algorithm for HCC in Cirrhosis ```mermaid flowchart TD A[Cirrhotic patient with nodule]:::outcome --> B{Nodule size?}:::decision B -->|<10 mm| C[Surveillance]:::action B -->|10-20 mm| D{AFP + imaging?}:::decision B -->|>20 mm| E{Imaging hallmark?}:::decision D -->|Both positive| F[HCC diagnosed]:::outcome D -->|One positive| G[Check PIVKA-II]:::action E -->|Arterial enhancement + washout| H[HCC diagnosed]:::outcome E -->|Atypical| G G -->|PIVKA-II elevated| I[HCC likely]:::outcome G -->|PIVKA-II normal| J[Benign nodule]:::outcome ``` ### Comparison: AFP vs PIVKA-II | Feature | AFP | PIVKA-II | |---------|-----|----------| | **Cutoff for HCC** | >400 ng/mL | >40 mAU/mL | | **Sensitivity** | 60–70% | 40–50% | | **Specificity (in cirrhosis)** | 80–85% | 95%+ | | **Elevated in benign cirrhosis** | Yes (mild) | Rare | | **Detects AFP-negative HCC** | — | ~40% | | **Best use** | Screening + diagnosis | Confirmation, AFP-negative cases | **High-Yield:** The AASLD and EASL guidelines recommend HCC diagnosis in cirrhosis when: - Nodule >20 mm with arterial enhancement + washout on one imaging modality, OR - Nodule 10–20 mm with both imaging hallmarks on two modalities, OR - Nodule 10–20 mm with imaging hallmark + AFP >400 ng/mL, OR - **Nodule with AFP >400 ng/mL + PIVKA-II >40 mAU/mL** (even if imaging atypical) **Clinical Pearl:** PIVKA-II is particularly useful in: - Patients with chronic hepatitis B (higher HCC risk even at lower AFP) - Distinguishing HCC from hepatic adenoma or focal nodular hyperplasia - Monitoring HCC recurrence post-treatment (rising PIVKA-II suggests recurrence before imaging changes) ### Why Other Options Fail Elevated bilirubin and PT are features of cirrhosis severity, not HCC discrimination. Portal vein thrombosis, while associated with HCC, also occurs in advanced cirrhosis without malignancy. GGT elevation is non-specific and present in many liver conditions.